Abstract | OBJECTIVES: METHODS: Patients were randomized to one of six treatment arms: placebo or OKZ (60 mg/120 mg/240 mg every four weeks [Q4W]; or 60 mg/120 mg every two weeks [Q2W]); stratified by country and number of prior anti-TNFs. Primary efficacy variable was Week 12 change from baseline (CFB) in DAS28 CRP for 4-week cumulative dose groups of OKZ and placebo; secondary efficacy variables were Week 12 ACR20/ACR50/ACR70 response rates. Patients continued MTX treatment from baseline, without additional csDMARDs. RESULTS: Of 119 randomized patients, 88.2% completed the study. Greater improvements in DAS28(CRP) mean CFB at Week 12 were observed in all OKZ 4-week cumulative dose groups (60 mg/120 mg/240 mg) versus placebo (p < 0.0001). Week 12 ACR20/ACR50 response rates were higher in all OKZ cumulative dose groups versus PBO (p < 0.05). Incidences of adverse events were similar across OKZ 4-week cumulative dose groups (76.9-84.4%) and placebo (82.8%) with no deaths. CONCLUSIONS: OKZ demonstrated improvements in efficacy variables versus placebo in Asian patients with moderately-to-severely active RA who had previously failed anti-TNF therapy. The safety profile was as expected for this class of drug.
|
Authors | Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Kanzo Amano, Ryuji Nagamine, Won Park, Kazuko Shiozawa, Michishi Tsukano, James Cheng-Chung Wei, Jing Shao, Osamu Togo, Hideki Mashimo |
Journal | Modern rheumatology
(Mod Rheumatol)
Vol. 26
Issue 1
Pg. 15-23
( 2016)
ISSN: 1439-7609 [Electronic] England |
PMID | 26358841
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- TNF protein, human
- Tumor Necrosis Factor-alpha
- olokizumab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Treatment Outcome
- Tumor Necrosis Factor-alpha
|